Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRT + XELOX + bevacizumab + atezolizumab for liver-dominant metastatic MSS colorectal cancer
2024-517204-11-00Phase 2Authorised
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, bevacizumab, capecitabine and oxaliplatin in colorectal cancer (CRC), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Progression-free survival at 9 months. Planned start Aug 2024; status: authorised.
02
Drugs
atezolizumabbevacizumabcapecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-517204-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517204-11-00.